No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Pharmaceuticals
Operating globally, Kyowa Kirin Co., Ltd. is a pharmaceutical company focused on the discovery, development, manufacturing, and marketing of innovative medical therapies. The company's core areas of expertise span oncology, nephrology, central nervous system disorders, and immunology. Its extensive product portfolio includes established medications such as ABSTRAL, a sublingual fentanyl formulation for managing breakthrough pain in cancer patients; ALLELOCK, an antihistamine for various allergic conditions; and CONIEL, a calcium channel blocker prescribed for hypertension and angina. Kyowa Kirin also provides a range of advanced biological and specialized treatments. These encompass Crysvita, a recombinant human monoclonal IgG1 antibody targeting fibroblast growth factor 23, and blood-related therapies like ESPO (human erythropoietin), NESP (an erythropoiesis stimulating agent), and GRAN (a human colony-stimulating factor). Further products in its lineup address diverse medical needs: G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for opioid-induced constipation; Nouriast/Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. Other significant offerings are PecFent, a nasally administered spray; POTELIGEO, a humanized monoclonal antibody targeting CC chemokine receptor 4; REGPARA for secondary hyperparathyroidism; Romiplate/Nplate, a recombinant protein promoting platelet production; and SANCUSO for managing nausea and vomiting. Beyond its current offerings, Kyowa Kirin is actively involved in pipeline development, notably through a strategic collaboration with Amgen Inc. for the joint development and commercialization of KHK4083. This Phase 3-ready, fully human anti-OX40 monoclonal antibody is being developed to treat atopic dermatitis. Established in Tokyo, Japan, in 1949, the company changed its name from Kyowa Hakko Kirin Co., Ltd. to Kyowa Kirin Co., Ltd. in June 2019. It operates as a subsidiary of Kirin Holdings Company, Limited.
www.kyowakirin.co.jpNo one on the platform currently holds 4151.T.
No tracked institution reports a position in 4151.T as of their last filing.
No one on the platform has traded 4151.T yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 11.2% | 13.3% | 10.5% | — | — | — |
| Rev. Growth % | 0.3% | 9.3% | ||||
| Profit Margin % | 13.5% | 14.4% | 13.6% | |||
| Free Cash Flow Margin % | 11.9% | 14.7% | 14.5% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $530.2B | +9.6% | $153.86 | $140.81–$184.34 | — | 11 |
| 2027 | $539.9B | +1.8% | $181.78 | $153.58–$206.38 | — | 11 |
| 2028 | $547.6B | +1.4% | $178.30 | $144.60–$221.33 | — | 10 |
| 2029 | $577.5B | +5.5% | $186.28 | $175.15–$194.28 | — | 4 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 2 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-03 | $33.11 | $35.49 | +7.2% |
| 2026-05-07 | $27.46 | $22.99 | -16.3% |
| 2026-02-09 | $40.88 | $65.79 | +60.9% |
| 2025-10-29 | $33.39 | $31.10 | -6.9% |
| 2025-07-30 | $31.83 | $19.40 | -39.1% |
| 2025-05-01 | $26.11 | $11.78 | -54.9% |
| 2025-02-05 | $29.61 | $7.86 | -73.5% |
| 2024-10-31 | $35.34 |
| $34.44 |
| -2.5% |
| +2.65% |
| $703.2B |
| — |
| 4523.TEisai Co., Ltd. | $4743.00 | +1.82% | $1.34T | — |
| 4528.TOno Pharmaceutical Co., Ltd. | $2337.50 | +0.75% | $1.10T | — |
Source: Financial Modeling Prep · peers by sector/industry